US 12,441,701 B2
Solid state forms of roluperidone and salts thereof
Dijana Skalec Samec, Jastrebarsko (HR); and Lorena Kordic, Rab (HR)
Assigned to TAPI CZECH INDUSTRIES S.R.O., Komarov (CZ)
Appl. No. 17/621,284
Filed by TAPI CZECH INDUSTRIES S.R.O, Opava-Komarov (CZ)
PCT Filed Jun. 29, 2020, PCT No. PCT/US2020/040091
§ 371(c)(1), (2) Date Dec. 21, 2021,
PCT Pub. No. WO2020/264486, PCT Pub. Date Dec. 30, 2020.
Claims priority of provisional application 62/942,800, filed on Dec. 3, 2019.
Claims priority of provisional application 62/928,453, filed on Oct. 31, 2019.
Claims priority of provisional application 62/878,902, filed on Jul. 26, 2019.
Claims priority of provisional application 62/867,957, filed on Jun. 28, 2019.
Prior Publication US 2022/0356165 A1, Nov. 10, 2022
Int. Cl. C07D 401/06 (2006.01)
CPC C07D 401/06 (2013.01) [C07B 2200/13 (2013.01)] 20 Claims
 
1. A crystalline form of roluperidone HCl designated as Form 4, which is characterized by data selected from one or more of the following:
(a) a PXRD pattern having peaks at 9.8, 12.3, 20.5 and 25.1 degrees 2-theta±0.2 degrees 2-theta;
(b) a PXRD pattern having peaks at 9.8, 11.6, 12.3, 20.5 and 25.1 degrees 2-theta±0.2 degrees 2-theta; and
(c) a PXRD pattern substantially as depicted in FIG. 5.